Trial Profile
Phase 2A, Double-blind, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Saroglitazar Mg 4 mg Tablet Vs Placebo for Treating NAFLD in Women With Polycystic Ovary Syndrome (PCOS)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms EVIDENCES VII
- Sponsors Zydus Discovery DMCC
- 06 Aug 2023 Planned End Date changed from 1 Mar 2023 to 1 Jul 2024.
- 06 Aug 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2024.
- 23 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Mar 2023.